Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:85
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
下载
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [31] Bosentan therapy for pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease: A multicenter cooperation
    Schulze-Neick, I
    Gilbert, N
    Ewert, R
    Witt, C
    Gruenig, E
    Olschewski, H
    Borst, MM
    Hoeper, MM
    Lange, PE
    CIRCULATION, 2004, 110 (17) : 652 - 652
  • [32] The Treatment of Congenital Heart Disease Associated Pulmonary Arterial Hypertension (PAH) with Sildenafil
    Crackett, R. M.
    Foggo, B. A.
    Day, M. B.
    Small, T.
    Mackay, L. S.
    Fisher, A. J.
    Lordan, J. L.
    MacGowan, G.
    Corris, P. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [33] Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism
    Duffels, M. G. J.
    van der Plas, M. N.
    Surie, S.
    Winter, M. M.
    Bouma, B. J.
    Groenink, M.
    van Dijk, A. P. J.
    Hoendermis, E. S.
    Berger, R. M. F.
    Bresser, P.
    Mulder, B. J. M.
    NETHERLANDS HEART JOURNAL, 2009, 17 (09) : 334 - +
  • [34] CLINICAL EFFICACY OF BOSENTAN OF BABIES WITH CONGENITAL HEART DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
    Zhang, X. Z.
    Wang, Q.
    Zhang, S. J.
    Liu, S.
    Sun, J. J.
    Li, J.
    Ming, L.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 9 - 9
  • [35] Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension
    Li, Ying
    Wang, Yao
    Liu, Shaohua
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11522 - 11530
  • [36] Carotid Arterial Stiffness in Patients with Congenital Heart Disease-Related Pulmonary Hypertension Assessed with Radio Frequency Data Technique
    Hou, Ying
    Yuan, Li-Jun
    Xing, Chang-Yang
    Shang, Fu-Jun
    Duan, Yun-You
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2015, 32 (11): : 1676 - 1680
  • [37] Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome
    Raposo-Sonnenfeld, Ines
    Otero-Gonzalez, Isabel
    Blanco-Aparicio, Marina
    Ferrer-Barba, Angela
    Medrano-Lopez, Constancio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (04): : 366 - 372
  • [38] The Efficacy and Safety of Sildenafil in Patients With Pulmonary Arterial Hypertension Associated With the Different Types of Congenital Heart Disease
    Zeng, Wei-Jie
    Lu, Xian-Ling
    Xiong, Chang-Ming
    Shan, Guang-Liang
    Liu, Zhi-Hong
    Ni, Xin-Hai
    Gu, Qing
    Zhao, Zhi-Hui
    Li, Jian-Jun
    He, Jian-Guo
    CLINICAL CARDIOLOGY, 2011, 34 (08) : 513 - 518
  • [39] Pulmonary hypertension associated with congenital heart disease and Eisenmenger syndrome
    Calderon-Colmenero, Juan
    Sandoval Zarate, Julio
    Beltran Gamez, Miguel
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2015, 85 (01): : 32 - 49
  • [40] Pulmonary Hypertension in Congenital Heart Disease Beyond Eisenmenger Syndrome
    Krieger, Eric V.
    Leary, Peter J.
    Opotowsky, Alexander R.
    CARDIOLOGY CLINICS, 2015, 33 (04) : 599 - +